Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Somatix Therapy
Alameda, California, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Somatix Therapy was a pioneering biotechnology company focused on the development of ex vivo and in vivo gene therapies. Founded in the late 1980s, the company specialized in using retroviral vectors to engineer cells to produce therapeutic proteins. Their lead programs included genetically modified tumor cell vaccines for melanoma and renal cell carcinoma, as well as treatments for hemophilia and neurological diseases. In 1997, Somatix was acquired by Cell Genesys in an all-stock transaction, consolidating two of the leading players in the early gene therapy field.
- Therapeutic areas
- OncologyNeurologyHematology
- Modalities
- Gene therapyCell therapy
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Somatix Therapy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Somatix Therapy.